Optimized Diagnosis and Precision Medicine of MODY

Type 2 Diabetes Clinical Trial

Official title:

Optimized Diagnosis and Precision Medicine of MODY (Maturity-Onset Diabetes of the Young)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06111833
• Other study ID #: CF23186B
• Status: Recruiting
• Start date: May 22, 2023
• Est. completion date: May 21, 2028

Study information

• Verified date: October 2023
• Source: Taichung Veterans General Hospital
• Contact: Yi-Jing Sheen, MD. PHD
• Phone: 886-4-2359-2525
• Email: docmedjean[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observation is to establish a complete registry for the clinical manifestations, environment, genetic, and other related gene variation information of young-onset diabetic patients. Moreover, according to the physiological and pathological mechanisms of different genes, the impact on the clinical characteristics of diabetes, the therapeutic response to drugs, and the impact on complications will be analyzed. The main questions are: 1. The distribution of different types of MODY 2. The phenotypes and clinical characteristics of different types of MODY 3. Response to antidiabetic drugs among different types of MODY Once the participant is enrolled, their questionnaire information (including disease course and development, health history, family history, drug history, etc.), medication, outpatient/inpatient medical history, etc. will be collected and logged in. Blood and urine samples will also be collected for biochemical tests genetic testing, etc. At the same time, the investigators will conduct a continuous follow-up on a regular basis (3 months, 6 months, 12 months, 24 months, and 5 years after the study subject is enrolled). Young-onset type 2 diabetes will be compared to see the difference in clinical presentations and responses to antidiabetic drugs.

Description:

Diabetes and its complications rank among the top ten death causes in Taiwan. In Taiwan, besides the high prevalence, diabetes also shows a trend in younger people. Compared with type 2 diabetes which typically develops at older ages, young-onset diabetes (YOD) has a faster decline in the function of islet cells and a higher risk of complications. These young-onset diabetic patients may belong to different subtypes, and each subtype has different clinical manifestations or genetic characteristics, while the physiological and pathological mechanisms behind them are very complex and closely affect the subsequent treatment decisions. Among young-onset diabetes, maturity-onset diabetes of the young (MODY) has the most obvious genetic predisposition and family history. If the diagnosis is confirmed, it may be possible to directly target the unique defect of the relevant gene and accurately select the appropriate drug therapy to help patients achieve good blood sugar control as soon as possible. This five-year proposal is aimed to target 1,500 young-onset diabetic patients (case group) as well as 500 young-onset, but not MODY, diabetic patients (control group). Once the study subject is enrolled, their questionnaire information (including disease course and development, health history, family history, drug history, etc.), medication, outpatient/inpatient medical history, etc. will be collected and logged in. Blood and urine samples will also be collected for biochemical tests genetic testing, etc. At the same time, the investigators will conduct a continuous follow-up on a regular basis (3 months, 6 months, 12 months, 24 months, and 5 years after the study subject is enrolled). The aim of this proposal is to establish a complete registry for the clinical manifestations, environment, genetic, and other related gene variation information of young-onset diabetic patients. Moreover, according to the physiological and pathological mechanisms of different genes, the impact on the clinical characteristics of diabetes, the therapeutic response to drugs, and the impact on complications will be analyzed. It is expected that different subtypes of early-onset diabetes can be established for genetic counseling, prevention, health education, and treatment selection strategies to achieve good blood sugar and other metabolic control in time, so as to achieve individualized precision medical prevention and treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: May 21, 2028
• Est. primary completion date: April 21, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Case Group Diagnosis of diabetes at or before 25 years of age. BMI (Body Mass Index) of 25 kg/m² or lower. Having at least one parent diagnosed with type 2 diabetes.

2. Family Group Direct blood relatives of the case group, including brothers and sisters of the case group, who have contacted the research team through the subjects. Expressing willingness to participate in this study after granting informed consent.

3. Control Group Diagnosis of diabetes occurred at or before the age of 40, and the individual lacks typical MODY (Maturity-Onset Diabetes of the Young) characteristics. At least one parent has been diagnosed with type 2 diabetes.

Exclusion Criteria:

1. Confirmed Diagnosed with type 1 diabetes.

2. Under 18 years of age.

3. Unable to personally provide informed consent.

4. Patients with unrelieved leukemia.

5. Patients who have undergone chemotherapy or radiation therapy for cancer within the last 12 months.

6. Cases that have received a blood transfusion within the last six months.

7. Unwilling or unable to continue treatment follow-up at this hospital.

Related Conditions & MeSH terms

• Diabetes Complications
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Locations

Country	Name	City	State
Taiwan	Taichung veterans general hospital	Taichung

Sponsors (2)

Lead Sponsor	Collaborator
Taichung Veterans General Hospital	National Health Research Institutes, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose control	serum concentration of Fasting glucose (mg/dl) HbA1C (%)	3 months
Primary	Genetic testing for evaluate the different types of MODY	Genotype evaluate by WES: Pathogenic or likely pathogenic Vairants rate (%)	1 year
Secondary	Renal function	Concentration of urine albumin-creatinine ratio: UACR (mg/g); Serum creatinine mg/dL	3 months
Secondary	Sudomotor function	value of Electrochemical Skin Conductance: µS	1 year